---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-24-000093"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:09:07.006909+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience appoints Paul Grayson as Chairman; CEO Dhillon gets salary hike and stock options

## Summary
- Paul Grayson appointed Chairman effective Oct 25, 2024; CEO Punit Dhillon resigns as Chairman, remains on Board.
- CEO Dhillon's base salary increased to $610,000; CFO Arsenault's to $450,000, effective Jan 1, 2025.
- Stock options granted: Dhillon 650,000 shares, Arsenault 125,000 shares; 10-year term, 48-month vesting.
- Grayson is independent director; currently CEO of Radionetics Oncology, former CEO of Tentarix and founder at Fate Therapeutics.

## SEC filing metadata
- accession: 0001516551-24-000093
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000093/0001516551-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000093/skye-20241028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-24-000093
- JSON: https://secwatch.observer/filing/0001516551-24-000093.json
- Plain text: https://secwatch.observer/filing/0001516551-24-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.